 For the 3 months ending September 30, 2022, BioNTech SE produced 3.65 billion in revenues for its Covid-19 vaccine Comirnaty. BioNTech has potential for Covid-19 market expansion with an enhanced spike protein vaccine plus many other vaccine candidates being advanced. 